Treg play­er Gen­tiBio turns to lay­offs; Cen­tu­ry Ther­a­peu­tics CEO de­parts

Treg biotech Gen­tiBio re­cent­ly en­act­ed lay­offs a lit­tle more than six months af­ter lin­ing up a pact with Bris­tol My­ers Squibb that could bal­loon to $1.9 bil­lion.

“Sev­er­al weeks ago, we im­ple­ment­ed a rel­a­tive­ly small re­duc­tion in force to po­si­tion us best to re­spond to the chal­leng­ing biotech macroen­vi­ron­ment and pro­long our run­way,” CEO Adel Na­da con­firmed to End­points News in an email. Na­da, de­clin­ing to dis­close the size of the re­duc­tion, said the lay­offs won’t im­pact op­er­a­tions nor the biotech’s col­lab­o­ra­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER